New Capital Management LP grew its holdings in Pfizer Inc. (NYSE:PFE) by 150,000.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,002 shares of the biopharmaceutical company’s stock after purchasing an additional 3,000 shares during the period. New Capital Management LP’s holdings in Pfizer were worth $98,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. New England Investment & Retirement Group Inc. purchased a new stake in Pfizer in the first quarter worth $26,000. Lion Street Advisors LLC purchased a new stake in Pfizer in the first quarter worth $27,000. Benjamin Edwards Inc. increased its stake in Pfizer by 49.8% in the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 335 shares during the period. Disciplined Investments LLC increased its stake in Pfizer by 43.3% in the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 347 shares during the period. Finally, Efficient Wealth Management LLC bought a new position in shares of Pfizer during the 1st quarter worth $50,000. Institutional investors and hedge funds own 70.28% of the company’s stock.
PFE stock traded down $0.34 during trading on Wednesday, reaching $33.69. 12,890,956 shares of the company traded hands, compared to its average volume of 33,425,040. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $44.10. The business has a 50 day simple moving average of $35.11 and a 200 day simple moving average of $36.13. The company has a market capitalization of $189.03 billion, a price-to-earnings ratio of 12.01, a price-to-earnings-growth ratio of 2.70 and a beta of 0.68. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.78 and a current ratio of 1.02.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The company had revenue of $12.03 billion for the quarter, compared to the consensus estimate of $11.38 billion. During the same quarter last year, the company earned $0.85 earnings per share. The firm’s revenue for the quarter was down 8.3% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.88 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.51%. The ex-dividend date of this dividend is Thursday, July 30th. Pfizer’s dividend payout ratio is presently 51.53%.
A number of research firms have recently issued reports on PFE. JPMorgan Chase & Co. dropped their price target on Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, June 1st. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a research report on Monday, May 4th. TheStreet raised Pfizer from a “c+” rating to a “b” rating in a research report on Monday, June 1st. Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price target on shares of Pfizer in a research report on Thursday, March 19th. Finally, Morgan Stanley dropped their price target on Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 2nd. Ten research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.72.
In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the sale, the senior vice president now owns 7,542 shares of the company’s stock, valued at $272,492.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Douglas M. Lankler sold 65,000 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total value of $2,460,250.00. Following the completion of the sale, the executive vice president now directly owns 135,375 shares of the company’s stock, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. In the last three months, insiders sold 69,362 shares of company stock valued at $2,622,691. Corporate insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.